Filtern
Volltext vorhanden
- ja (22)
Gehört zur Bibliographie
- ja (22)
Dokumenttyp
Sprache
- Englisch (22)
Schlagworte
- adrenocortical carcinoma (3)
- hypercortisolism (3)
- miRNA (3)
- CYP2W1 (2)
- Cushing’s syndrome (2)
- FGF-pathway (2)
- FGFR (2)
- adrenal tumours (2)
- adrenocortical cancer (2)
- adrenocortical tumors (2)
- biomarker (2)
- cortisol (2)
- mitotane (2)
- mortality (2)
- neuroendocrine tumor (2)
- osteoporosis (2)
- prognosis (2)
- vitamin D (2)
- ACC (1)
- ACTH (1)
- BIRC7 (1)
- CTNNB1 (1)
- CXCR4 (1)
- CXCR7 (1)
- CYP2B6 (1)
- Cushing’s disease (1)
- EMT (1)
- FGFR-inhibitors (1)
- LCNEC (1)
- MEN1 (1)
- NR3C1 (1)
- RNA Expression (1)
- RNAScope (1)
- SNP (1)
- USP8 (1)
- adjuvant therapy (1)
- adjuvant treatment (1)
- adrenal glands (1)
- adrenal imaging (1)
- adrenal tumor (1)
- adrenocortical adenoma (1)
- adrenocortical carcinoma (ACC) (1)
- adrenocortical development (1)
- adrenocortical tissues (1)
- adrenocortical tumor (1)
- age (1)
- autonomous cortisol secretion (1)
- bioinformatic clustering (1)
- biomarker prediction (1)
- blood pressure (1)
- bone (1)
- bone metabolism (1)
- cancer (1)
- cancer treatment (1)
- carcinomas (1)
- cardiovascular diseases (1)
- cardiovascular events (1)
- cardiovascular risk factors (1)
- caspase-3 (1)
- chemokine receptor (1)
- chronotype (1)
- circadian rhythms (1)
- cortisol-producing adenoma (1)
- dexamethasone suppression test (1)
- drug therapy (1)
- efficacy (1)
- endocrine cancer (1)
- epidemiology (1)
- epithelial markers (1)
- genetic analysis (1)
- glucocorticoid excess (1)
- hormones (1)
- immune response (1)
- immunity (1)
- immunohistochemistry techniques (1)
- immunotherapy (1)
- in silico analysis (1)
- isturisa (1)
- livin (1)
- lncRNA (1)
- lymph nodes (1)
- lymphocytes (1)
- machine learning (1)
- medical therapy (1)
- menopause (1)
- mesenchymal markers (1)
- metyrapone (1)
- miR-182-5p (1)
- miR-183 cluster (1)
- mineral bone density (1)
- morbidity (1)
- neurofibromatosis type 1 (1)
- normal adrenal glands (1)
- obesity (1)
- osilodrostat (1)
- paraganglioma (1)
- patient survival (1)
- personalised medicine (1)
- pheochromocytoma (1)
- predictive marker (1)
- prognostic marker (1)
- prognostic markers (1)
- pulmonary cancer (1)
- radiotherapy (RT) (1)
- recurrence (1)
- recurrence free survival (1)
- recurrence-free survival (1)
- serotonin (1)
- surgery (1)
- surgical oncology (1)
- surveillance (1)
- survival (1)
- t-lymphocytes (1)
- therapy (1)
- timing (1)
- tumor (1)
- tumor microenvironment (1)
- tumor-infiltrating (1)
- type 2 diabetes (1)
- unsupervised clustering (1)
Institut
- Medizinische Klinik und Poliklinik I (22)
- Pathologisches Institut (7)
- Comprehensive Cancer Center Mainfranken (5)
- Klinik und Poliklinik für Nuklearmedizin (2)
- Center for Computational and Theoretical Biology (1)
- Institut für Klinische Biochemie und Pathobiochemie (1)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (1)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (1)
- Klinik und Poliklinik für Strahlentherapie (1)
- Medizinische Klinik und Poliklinik II (1)
Neurofibromatosis type 1 (NF1) is a genetic multisystemic autosomal dominant disorder determining reduced life expectancy due to higher risk of developing benign and malignant tumors. Low levels of vitamin D and reduced bone mineral density (BMD) have been reported in young patients with NF1. However, correlation between vitamin D and NF1 phenotype needs to be elucidated. Aim of this study was to assess vitamin D levels and bone metabolism in NF1 patients, analyzing potential correlations with clinical phenotype. A cross-sectional study was carried out in a monocentric series of NF1 patients, evaluating genotype, clinical phenotype, BMD, biochemical evaluation with focus on serum 25OH-vitamin D, parathyroid hormone (PTH), calcium and phosphate levels. Correlations between clinical manifestations, neurofibromas, and vitamin D status have been studied in comparison with healthy controls. 31 NF1 adult patients were matched for sex, age and body mass index with 31 healthy controls. A significantly difference in vitamin D level emerged in NF1 patients compared to controls. Interestingly low vitamin D levels correlated with a more aggressive phenotype and with a bigger size of neurofibromas. These data underline that vitamin D deficiency/insufficiency may play a role in clinical severity of neurofibromas in patients with NF1, suggesting the need to check bone status and replace vitamin D in these patients.
A relevant issue on the treatment of adrenocortical carcinoma (ACC) concerns the optimal duration of adjuvant mitotane treatment. We tried to address this question, assessing whether a correlation exists between the duration of adjuvant mitotane treatment and recurrence-free survival (RFS) of patients with ACC. We conducted a multicenter retrospective analysis on 154 ACC patients treated for ≥12 months with adjuvant mitotane after radical surgery and who were free of disease at the mitotane stop. During a median follow-up of 38 months, 19 patients (12.3%) experienced recurrence. We calculated the RFS after mitotane (RFSAM), from the landmark time-point of mitotane discontinuation, to overcome immortal time bias. We found a wide variability in the duration of adjuvant mitotane treatment among different centers and also among patients cared for at the same center, reflecting heterogeneous practice. We did not find any survival advantage in patients treated for longer than 24 months. Moreover, the relationship between treatment duration and the frequency of ACC recurrence was not linear after stratifying our patients in tertiles of length of adjuvant treatment. In conclusion, the present findings do not support the concept that extending adjuvant mitotane treatment over two years is beneficial for ACC patients with low to moderate risk of recurrence.